{"id":403837,"date":"2020-12-21T11:00:37","date_gmt":"2020-12-21T16:00:37","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=403837"},"modified":"2020-12-21T11:00:37","modified_gmt":"2020-12-21T16:00:37","slug":"oncopeptides-enrolls-the-first-patient-in-the-phase-3-lighthouse-combination-study-in-multiple-myeloma","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-enrolls-the-first-patient-in-the-phase-3-lighthouse-combination-study-in-multiple-myeloma\/","title":{"rendered":"Oncopeptides enrolls the first patient in the phase 3 LIGHTHOUSE combination study in multiple myeloma"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n STOCKHOLM<\/span>, Dec. 21, 2020<\/span> \/PRNewswire\/ —\u00a0Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), today announced that the first patient has been dosed in the phase 3 LIGHTHOUSE study, evaluating the efficacy and safety of\u00a0a\u00a0triple combination therapy with\u00a0melflufen\u00a0plus dexamethasone and subcutaneous daratumumab compared to daratumumab alone. The phase 3 LIGHTHOUSE study\u00a0is a\u00a0randomized, open-label study in patients with relapsed refractory multiple myeloma who are refractory to an immunomodulatory agent and a proteasome\u00a0inhibitor or who have had at least three prior lines of therapy, including these agents.\u00a0<\/p>\n

“Following the encouraging results of our ANCHOR study this is an important study to further evaluate the potential role of melflufen in triplet regimens”, says Klaas Bakker<\/span>, MD, PhD, Chief Medical Officer, Oncopeptides AB. “There is an imminent need for additional therapeutic options as myeloma patients become multi-resistant earlier in their treatment journey. A positive outcome may potentially support the use of melflufen as combination therapy with daratumumab in earlier stages of multiple myeloma”.<\/p>\n

Additional study information can be found on https:\/\/clinicaltrials.gov\/<\/a>, identifier: NCT04649060.<\/p>\n

\n For more information, please contact:<\/b>\n <\/p>\n

\n Klaas Bakker<\/span>, MD, PhD, Chief Medical Officer, Oncopeptides AB
E-mail: klaas.bakker@oncopeptides.com<\/a>
Cell: +44 7818 523 903<\/p>\n

Linda Holmstr\u00f6m, Director Investor Relations, Oncopeptides AB
E-mail: linda.holmstrom@oncopeptides.com<\/a>
Cell: + 46 70\u00a0873 40 95<\/p>\n

Rein Piir, Senior Advisor Investor Relations, Oncopeptides AB
E-mail: rein.piir@oncopeptides.com<\/a>
Cell: +46 70 853 72 92<\/p>\n

The information was submitted for publication on December 21, 2020<\/span> at 16:45 (CET).<\/p>\n

\n About melflufen<\/b>\n <\/p>\n

Melflufen (INN melphalan flufenamide)\u00a0is a first in class peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells. Melflufen is rapidly taken up by myeloma cells due to its high lipophilicity and is immediately hydrolyzed by peptidases to release an entrapped hydrophilic alkylator payload. Aminopeptidases are overexpressed in tumor cells and are even more pronounced in advanced cancers and tumors with a high mutational burden. In vitro, melflufen is 50-fold more potent in myeloma cells than the alkylator payload itself due to the increased intracellular alkylator concentration. Melflufen displays cytotoxic activity against myeloma cell lines resistant to other treatments, including alkylators, and has also demonstrated inhibition of DNA repair induction and angiogenesis in preclinical studies.\u00a0In the pivotal phase 2 HORIZON study melflufen plus dexamethasone demonstrated encouraging efficacy and a clinically manageable safety profile in heavily pretreated patients with relapsed refractory multiple myeloma, with primarily hematologic Adverse Events (AE) and a low incidence of non-hematologic AEs. \u00a0<\/p>\n

\n About Oncopeptides <\/b>\n <\/p>\n

Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The lead product candidate melflufen, is a first in class peptide-drug conjugate that targets aminopeptidases and rapidly releases alkylating agents into tumor cells. Melflufen is in development as a new treatment for the hematological malignancy multiple myeloma and is being tested in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study.\u00a0Based on the results from the HORIZON study a New Drug Application has been submitted to the U.S. Food and Drug Administration, FDA, for accelerated approval of melflufen in combination with dexamethasone for treatment of adult patients with triple-class refractory multiple myeloma. The FDA,\u00a0has\u00a0granted the\u00a0New Drug Application a priority review, with a PDUFA date of February 28<\/span>, 2021.Oncopeptides’ global Headquarters is in Stockholm, Sweden<\/span> and the U.S. Headquarters is situated in Boston, Mass.<\/span> The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO. More information is available on\u00a0www.oncopeptides.com<\/a>.<\/p>\n

This information was brought to you by Cision http:\/\/news.cision.com<\/a><\/p>\n

\n https:\/\/news.cision.com\/oncopeptides-ab\/r\/oncopeptides-enrolls-the-first-patient-in-the-phase-3-lighthouse-combination-study-in-multiple-myelo,c3260303<\/a>\n <\/p>\n

The following files are available for download:<\/p>\n

\n\n\n
\n

\n
\n https:\/\/mb.cision.com\/Main\/15404\/3260303\/1352917.pdf<\/a>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n Press release – Oncopeptides enrolls the first patient in the phase 3 LIGHTHOUSE combination study<\/span>\n <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n

\n \"Cision\" View original content:http:\/\/www.prnewswire.com\/news-releases\/oncopeptides-enrolls-the-first-patient-in-the-phase-3-lighthouse-combination-study-in-multiple-myeloma-301196875.html<\/a><\/p>\n

SOURCE Oncopeptides AB<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire STOCKHOLM, Dec. 21, 2020 \/PRNewswire\/ —\u00a0Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), today announced that the first patient has been dosed in the phase 3 LIGHTHOUSE study, evaluating the efficacy and safety of\u00a0a\u00a0triple combination therapy with\u00a0melflufen\u00a0plus dexamethasone and subcutaneous daratumumab compared to daratumumab alone. The phase 3 LIGHTHOUSE study\u00a0is a\u00a0randomized, open-label study in patients with relapsed refractory multiple myeloma who are refractory to an immunomodulatory agent and a proteasome\u00a0inhibitor or who have had at least three prior lines of therapy, including these agents.\u00a0 “Following the encouraging results of our ANCHOR study this is an important study to further evaluate the potential role of melflufen in triplet regimens”, says Klaas Bakker, MD, PhD, Chief Medical Officer, Oncopeptides AB. “There is … <\/p>\n

Continue reading “Oncopeptides enrolls the first patient in the phase 3 LIGHTHOUSE combination study in multiple myeloma”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-403837","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nOncopeptides enrolls the first patient in the phase 3 LIGHTHOUSE combination study in multiple myeloma - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-enrolls-the-first-patient-in-the-phase-3-lighthouse-combination-study-in-multiple-myeloma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oncopeptides enrolls the first patient in the phase 3 LIGHTHOUSE combination study in multiple myeloma - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire STOCKHOLM, Dec. 21, 2020 \/PRNewswire\/ —\u00a0Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), today announced that the first patient has been dosed in the phase 3 LIGHTHOUSE study, evaluating the efficacy and safety of\u00a0a\u00a0triple combination therapy with\u00a0melflufen\u00a0plus dexamethasone and subcutaneous daratumumab compared to daratumumab alone. The phase 3 LIGHTHOUSE study\u00a0is a\u00a0randomized, open-label study in patients with relapsed refractory multiple myeloma who are refractory to an immunomodulatory agent and a proteasome\u00a0inhibitor or who have had at least three prior lines of therapy, including these agents.\u00a0 “Following the encouraging results of our ANCHOR study this is an important study to further evaluate the potential role of melflufen in triplet regimens”, says Klaas Bakker, MD, PhD, Chief Medical Officer, Oncopeptides AB. “There is … Continue reading "Oncopeptides enrolls the first patient in the phase 3 LIGHTHOUSE combination study in multiple myeloma"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-enrolls-the-first-patient-in-the-phase-3-lighthouse-combination-study-in-multiple-myeloma\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-21T16:00:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO30822&sd=2020-12-21\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncopeptides-enrolls-the-first-patient-in-the-phase-3-lighthouse-combination-study-in-multiple-myeloma\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncopeptides-enrolls-the-first-patient-in-the-phase-3-lighthouse-combination-study-in-multiple-myeloma\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Oncopeptides enrolls the first patient in the phase 3 LIGHTHOUSE combination study in multiple myeloma\",\"datePublished\":\"2020-12-21T16:00:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncopeptides-enrolls-the-first-patient-in-the-phase-3-lighthouse-combination-study-in-multiple-myeloma\\\/\"},\"wordCount\":643,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncopeptides-enrolls-the-first-patient-in-the-phase-3-lighthouse-combination-study-in-multiple-myeloma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO30822&sd=2020-12-21\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncopeptides-enrolls-the-first-patient-in-the-phase-3-lighthouse-combination-study-in-multiple-myeloma\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncopeptides-enrolls-the-first-patient-in-the-phase-3-lighthouse-combination-study-in-multiple-myeloma\\\/\",\"name\":\"Oncopeptides enrolls the first patient in the phase 3 LIGHTHOUSE combination study in multiple myeloma - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncopeptides-enrolls-the-first-patient-in-the-phase-3-lighthouse-combination-study-in-multiple-myeloma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncopeptides-enrolls-the-first-patient-in-the-phase-3-lighthouse-combination-study-in-multiple-myeloma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO30822&sd=2020-12-21\",\"datePublished\":\"2020-12-21T16:00:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncopeptides-enrolls-the-first-patient-in-the-phase-3-lighthouse-combination-study-in-multiple-myeloma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncopeptides-enrolls-the-first-patient-in-the-phase-3-lighthouse-combination-study-in-multiple-myeloma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncopeptides-enrolls-the-first-patient-in-the-phase-3-lighthouse-combination-study-in-multiple-myeloma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO30822&sd=2020-12-21\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO30822&sd=2020-12-21\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncopeptides-enrolls-the-first-patient-in-the-phase-3-lighthouse-combination-study-in-multiple-myeloma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oncopeptides enrolls the first patient in the phase 3 LIGHTHOUSE combination study in multiple myeloma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oncopeptides enrolls the first patient in the phase 3 LIGHTHOUSE combination study in multiple myeloma - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-enrolls-the-first-patient-in-the-phase-3-lighthouse-combination-study-in-multiple-myeloma\/","og_locale":"en_US","og_type":"article","og_title":"Oncopeptides enrolls the first patient in the phase 3 LIGHTHOUSE combination study in multiple myeloma - Market Newsdesk","og_description":"PR Newswire STOCKHOLM, Dec. 21, 2020 \/PRNewswire\/ —\u00a0Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), today announced that the first patient has been dosed in the phase 3 LIGHTHOUSE study, evaluating the efficacy and safety of\u00a0a\u00a0triple combination therapy with\u00a0melflufen\u00a0plus dexamethasone and subcutaneous daratumumab compared to daratumumab alone. The phase 3 LIGHTHOUSE study\u00a0is a\u00a0randomized, open-label study in patients with relapsed refractory multiple myeloma who are refractory to an immunomodulatory agent and a proteasome\u00a0inhibitor or who have had at least three prior lines of therapy, including these agents.\u00a0 “Following the encouraging results of our ANCHOR study this is an important study to further evaluate the potential role of melflufen in triplet regimens”, says Klaas Bakker, MD, PhD, Chief Medical Officer, Oncopeptides AB. “There is … Continue reading \"Oncopeptides enrolls the first patient in the phase 3 LIGHTHOUSE combination study in multiple myeloma\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-enrolls-the-first-patient-in-the-phase-3-lighthouse-combination-study-in-multiple-myeloma\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-21T16:00:37+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO30822&sd=2020-12-21","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-enrolls-the-first-patient-in-the-phase-3-lighthouse-combination-study-in-multiple-myeloma\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-enrolls-the-first-patient-in-the-phase-3-lighthouse-combination-study-in-multiple-myeloma\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Oncopeptides enrolls the first patient in the phase 3 LIGHTHOUSE combination study in multiple myeloma","datePublished":"2020-12-21T16:00:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-enrolls-the-first-patient-in-the-phase-3-lighthouse-combination-study-in-multiple-myeloma\/"},"wordCount":643,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-enrolls-the-first-patient-in-the-phase-3-lighthouse-combination-study-in-multiple-myeloma\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO30822&sd=2020-12-21","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-enrolls-the-first-patient-in-the-phase-3-lighthouse-combination-study-in-multiple-myeloma\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-enrolls-the-first-patient-in-the-phase-3-lighthouse-combination-study-in-multiple-myeloma\/","name":"Oncopeptides enrolls the first patient in the phase 3 LIGHTHOUSE combination study in multiple myeloma - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-enrolls-the-first-patient-in-the-phase-3-lighthouse-combination-study-in-multiple-myeloma\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-enrolls-the-first-patient-in-the-phase-3-lighthouse-combination-study-in-multiple-myeloma\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO30822&sd=2020-12-21","datePublished":"2020-12-21T16:00:37+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-enrolls-the-first-patient-in-the-phase-3-lighthouse-combination-study-in-multiple-myeloma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-enrolls-the-first-patient-in-the-phase-3-lighthouse-combination-study-in-multiple-myeloma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-enrolls-the-first-patient-in-the-phase-3-lighthouse-combination-study-in-multiple-myeloma\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO30822&sd=2020-12-21","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO30822&sd=2020-12-21"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncopeptides-enrolls-the-first-patient-in-the-phase-3-lighthouse-combination-study-in-multiple-myeloma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Oncopeptides enrolls the first patient in the phase 3 LIGHTHOUSE combination study in multiple myeloma"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/403837","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=403837"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/403837\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=403837"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=403837"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=403837"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}